Introduction
============

Pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), hold great potential to differentiate into any cell type of the human body. Human PSC-derived cardiomyocytes (hPSC-CMs) provide the alternative strategies for myocardial repair, drug screening and disease modeling [@B1], [@B2]. However, the efficiency of cardiomyocyte differentiation is still not stable between cell lines [@B3], [@B4], and the immature characteristics of hPSC-CMs impair their applications for drug screening and disease modeling [@B5], [@B6].

The mature cardiomyocytes present fully-developed cells that resemble adult cardiomyocytes in structure and function, and have properties including an organized ultrastructure, an increased density of mitochondria, the ability to perform oxidative metabolism using fatty acid, and functional electrophysiology and calcium handling [@B7]-[@B10]. However, hPSC-CMs generated by current protocols are more similar to cardiomyocytes at embryonic or early fetal stages [@B9]. Previous reports have shown that electrical stimulation, small molecules, and tissue engineering can promote cardiomyocyte maturation [@B7], [@B11]-[@B13]. However, it is still difficult to obtain fully matured cardiomyocytes from hPSCs, and the mechanism for cardiomyocyte maturation is still largely unknown.

Retinoic acid (RA) is derived from vitamin A through two sequential dehydrogenation reactions, and acts as a ligand of nuclear RA receptors (RARs) [@B14]. Mice with mutant aldehyde dehydrogenase 1 family member A2 (*ALDH1A2*), a rate-limiting enzyme for RA synthesis, showed abnormal heart looping, trabeculation and cardiomyocyte differentiation during heart development [@B15]. In addition, RARs have been proven to be important for heart, outflow tract, and aortic arch development [@B16]. These results suggest that RA plays multiple roles during heart development. Recent studies have mainly focused on the effects of RA on the subtype differentiation of cardiomyocytes. RA treatment with different protocols can promote atrial-like, sinoatrial-like and epicardial-like cell differentiation [@B1], [@B17]-[@B19]. However, the roles of RA in cardiomyocyte maturation remain unclear.

In this study, we found that genes involved in RA synthesis and signaling showed specific expression patterns in different germ layers, providing new clues for understanding mesoderm differentiation. Furthermore, we systemically studied the roles of RA in cardiomyocyte differentiation and maturation. Our results showed that the RA treatment during the time window of the lateral mesoderm stage could promote cardiomyocyte differentiation and that RA treatment post beating could promote maturation of hESC-CMs, as indicated by the increased sarcomere length, mitochondria density, fatty acid metabolism, and the enhanced electrophysiological maturation and calcium handling.

Materials and Methods
=====================

Mice maintenance and germ layer separation
------------------------------------------

The ICR mice were housed under specific-pathogen-free (SPF) conditions in the animal facilities at Soochow University. All experimental procedures involving animals were approved by the Laboratory Animal Research Committee of Soochow University. E7.5 embryos were dissected from the deciduas, and the germ layers were separated carefully with glass needles as previously reported [@B20], [@B21]. Samples were collected for RNA extraction.

Maintenance and differentiation of hESCs
----------------------------------------

The hESC lines (NKX2.5^eGFP/w^ HES3, H1 and H9-GCaMP6f) with passages 55-65 were routinely maintained and differentiated as described previously [@B22], [@B23]. In brief, the hESCs were cultured on feeder-free Matrigel (356231, Corning, USA) in E8 medium (A1517001, Thermo Fisher, USA). Before cardiomyocyte differentiation, the hESCs were passaged every 4 days at 80% confluence using 0.5 mM EDTA and re-plated at a density of 2 × 10^4^ cells/cm^2^. To initiate cardiomyocyte differentiation, the medium was changed with CDM3 (chemically defined medium, three components) containing 5 μM CHIR99021 (C-6556, LC Laboratories, USA) for 48 hours (day 0-2). After a 2-day culture in CDM3, the medium was changed with CDM3 containing 5 μM IWR-1 (I0161, Sigma, USA) for 48 hours (day 4-6). The subsequent culture was in CDM3. The medium was changed every day. Spontaneous beating was commonly observed on day 10. For cardiomyocyte purification, the cells were re-plated on gelatin-coated dishes in RPMI 1640 lacking of glucose and containing 5 mM sodium DL-lactate (L4263, Sigma, USA) from day 11 to day 15 of differentiation. RA (R2625, Sigma, USA) was dissolved in DMSO and added to the CDM3 at the indicated times for cardiomyocyte differentiation and maturation. The final concentration of RA was 1 μM, and the final concentration of DMSO was 0.05% in both groups.

Reverse transcription and quantitative real-time PCR
----------------------------------------------------

TRIzol reagent (15596026, Thermo Fisher, USA) was used to extract total RNA from the different samples. The total RNA was subjected to reverse transcription for single-strand cDNA synthesis using a Takara PrimeScript RT Reagent Kit (RR047A, Takara, Japan). Quantitative real-time PCR (qPCR) assays were performed and the results were analyzed using an Applied Biosystems StepOnePlus Real-Time PCR System (Thermo Fisher, USA). The *18S* rRNA was used as a reference gene for human mRNA quantification, and *Gapdh* was used as a reference gene for mouse mRNA quantification. The data were analyzed using the 2^-ΔΔCT^ method. All primers used for quantitative real-time PCR were listed in [Table S1](#SM0){ref-type="supplementary-material"} and [Table S2](#SM0){ref-type="supplementary-material"}.

RNA-seq analysis
----------------

After purification, the differentiated cardiomyocytes were treated with RA for 5 days and maintained in CDM3 for another 10 days. Cardiomyocytes were then collected in TRIzol reagent for RNA-seq analysis. Briefly, mRNA samples were purified from total RNA using poly-T oligo-attached magnetic beads and subjected to library preparation using NEBNext® UltraTM RNA Library Prep Kit for Illumina^®^ (E7530S, NEB, USA). Then the library preparations were sequenced on an Illumina Hiseq platform in Novogene company (China). The bam files were imported into the IGV software for coverage and splicing visualization. The splicing junctions were normalized using the total mapped reads. The fold change of junction reads/total mapped reads was calculated after RA treatment. Statistical significance was denoted by a fold change \> 1.5 or *p* \< 0.05, which was calculated with rMATS software.

Immunofluorescence staining
---------------------------

Cells were fixed in 4% paraformaldehyde for 20 minutes followed by the PBS-T washes. After permeabilization with 0.25% Triton X-100 for 10 minutes, the cells were blocked with 3% BSA for 1 hour at room temperature and incubated with anti-α-actinin antibody (ab9465, Abcam, USA) overnight at 4°C. After rinsing with PBS-T, the cells were incubated with Alexa Fluor 594 secondary antibody (715-585-151, Jackson ImmunoResearch, USA) at room temperature for 1 hour, and then the nuclei were stained with Hoechst 33342 (14533, Sigma, USA). Fluorescence images were acquired with an LSM 880 confocal laser scanning microscope (Zeiss, Germany). Each cardiomyocyte was analyzed using ImageJ software with standard analysis plugins for average sarcomere length and cell area. More than 60 cells were analyzed for each group [@B6], [@B13]. The antibodies used in this study are listed in [Table S3](#SM0){ref-type="supplementary-material"}.

Flow cytometry
--------------

Differentiated cells were dissociated into single cells with 0.25% trypsin-EDTA and fixed in 1% paraformaldehyde for 10 minutes. The anti-cardiac troponin T (TNNT2) antibody (MS-295-P1, Thermo Fisher, USA) and Alexa Fluor 647 secondary antibody (715-605-151, Jackson ImmunoResearch, USA) were used for flow cytometry analysis. Data were acquired and analyzed using Guava easyCyte^TM^ 8 (EMD Millipore, Germany).

Mitochondrial staining
----------------------

hESC-CMs were plated on the coverslips coated with 0.1% gelatin and cultured for 72 hours before staining. Mitochondrial staining was performed by incubating cells with prewarmed medium supplemented with 0.1 μM MitoTracker Red CMXRos for 20 minutes. After 3 washes with D-PBS, the cells were fixed and subsequently incubated with TNNT2 antibody, Alexa Fluor 488 secondary antibody (715-545-151, Jackson ImmunoResearch, USA) and Hoechst 33342 as described above. Mitochondria were visualized using an LSM 880 confocal laser scanning microscope (Zeiss, Germany).

MitoTracker Red flow cytometry
------------------------------

Cardiomyocytes were washed with D-PBS and then incubated with prewarmed medium supplemented with 0.1 μM MitoTracker Red CMXRos (M7512, ThermoFisher Scientific, USA) for 20 minutes. After 3 washes with D-PBS, the cells were dissociated into single cells using 0.25% trypsin-EDTA and fixed with 1% paraformaldehyde for 20 minutes. Then, the cells were washed with D-PBS and analyzed with Millipore Guava easyCyte 8 (EMD Millipore, USA).

Metabolic assays
----------------

A Seahorse XF24 Extracellular Flux Analyzer (Seahorse Bioscience, USA) was used to assess oxygen consumption rates (OCR) and extracellular acidification rates (ECAR). On day 30 of differentiation, cardiomyocytes were seeded onto the plates coated with 0.1% gelatin at 5 × 10^5^ cells/well. The Seahorse assays were carried out after 3 days of culture in an XF24 24-well plate. For the mitochondrial metabolism assay, one hour before the assay, the culture medium was re-placed with pH 7.4 unbuffered assay medium supplemented with 5.5 mM glucose (G7021, Sigma, USA), 1 mM sodium pyruvate (11360070, Thermo Fisher, USA), 2 mM GlutaMAX (35050061, Thermo Fisher, USA) or a combination of these substances. For the palmitate metabolism assay, cardiomyocytes were cultured in substrate-limited medium (DMEM, 0.5 mM glucose, 1 mM GlutaMAX, 0.5 mM carnitine (C0283, Sigma, USA), 1%FBS) for 24 hours. After 2 washes with FAO assay medium (111 mM NaCl, 4.7 mM KCl, 1.25 mM CaCl~2~, 2 mM MgSO~4~, 1.2 mM NaH~2~PO~4~, 0.5 mM carnitine and 5 mM HEPES; adjusted to PH 7.4 with NaOH), the cells were incubated in FAO assay medium for 45 minutes prior to the assay in a non-CO~2~ incubator. Then, 40 μM Etomoxir (ETO, an inhibitor of carnitine palmitoyltransferase-1) (E1905, Sigma, USA) or vehicle was added to each well for 15 minutes before starting the assay. The palmitate assay was started just after the addition of 200 μM sodium palmitate (P9767, Sigma, USA) in 0.1% BSA. Seahorse XF Cell Mito Stress Test compounds (103015-100, Agilent, USA) were added sequentially to achieve final concentrations of 2 μM oligomycin, 1.5 μM FCCP, and 2 μM rotenone/antimycin A (Rtn/AA). ETO-responsive OCR changes were used to confirm fatty acid metabolism. For the glycolysis assay, the culture media was re-placed with unbuffered assay medium. Glycolysis stress test compounds (103020-100, Agilent, USA) were added to achieve final concentrations of 10 mM glucose, 2 μM oligomycin, and 5 mM 2-DG. The OCR and ECAR values were further normalized to 10 μg of protein in each well. The protein concentrations were measured with a BCA kit (P0011, Beyotime Biotechnology, China).

Electrophysiology
-----------------

Action potentials (APs) recorded from spontaneous cardiomyocytes were conducted using the Axopatch 200B Microelectrode Amplifier (Molecular Devices, USA) in the current clamp mode. For whole-cell recording, cardiomyocytes were incubated in the bath solution containing 140 mM NaCl, 4 mM KCl, 1.2 mM CaCl~2~, 1 mM MgCl~2~, 10 mM HEPES, and 10 mM glucose, with pH adjusted to 7.4 with NaOH. The pipette solution consisted of 115 mM potassium aspartate, 15 mM KCl, 4 mM NaCl, 1 mM MgCl~2~, 5 mM Mg-ATP, 5 mM HEPES, and 5 mM EGTA, with pH adjusted to 7.2 with KOH. Data acquisition was performed using pClamp software. The action potential duration at 50% (APD~50~) and 90% (APD~90~) repolarization were calculated by Clampfit 10.3 software.

Calcium (Ca^2+^) handling assay
-------------------------------

H9-GCaMP6f hESC line was generated as previously report [@B24], and the differentiated cardiomyocytes were seeded onto confocal dishes. Intracellular calcium flux was captured using an LSM 880 confocal laser scanning microscope (Zeiss, Germany). Spontaneous Ca^2+^ transients were acquired by line scan mode with a sampling rate of 1 ms/line under the condition of 37 °C and 5% CO~2~. The amplitude of Ca^2+^ transient was expressed as normalized fluorescence signals (∆F/F0). The time to peak and decay time were recorded. All of these measurements were acquired for at least four beats in each video and averaged for comparison.

Chromatin immunoprecipitation (ChIP)-PCR
----------------------------------------

The ChIP assay was performed using EZ-ChIP kit (17-371, Millipore, USA) according to the manufacturer\'s protocol. Briefly, \~10^7^ cardiomyocytes were fixed with 1% formaldehyde to covalently crosslink proteins to DNA, followed by addition of glycine (0.125 M) to quench unreacted formaldehyde. After washed with cold PBS, cells were lysed in SDS lysis buffer and sonicated (10-12 sets of 15 seconds each at 15-second interval) on ice. Sheard crosslinked chromatin were immunoprecipitated with anti-RARα antibody (ab41934, Abcam, USA). Antibodies against RNA Polymerase II and mouse IgG in the EZ-ChIP kit were added as positive and negative control respectively. After DNA purification, semi-quantitative PCR was performed with primers specific to the two retinoic acid response elements (RAREs) in the promoter region of human *PGC1A*. The two RAREs were named as RARE1 (-229 bp \~ -212 bp: 5\'-AGGGTTATCTGGGGGCGA-3\') and RARE2 (-70 bp \~ -53 bp: 5\'-TGACTCTGAGATGCCCTC-3\'), respectively. The matched sequences of RAREs in *PGC1A* promoter were acquired from the JASPAR database. The primers used for ChIP-PCR were listed in [Table S4](#SM0){ref-type="supplementary-material"}, while primers for human *GAPDH* in EZ-ChIP kit were used as control primers.

Statistical analysis
--------------------

Comparisons between two groups were performed using Student\'s *t*-test. Comparisons among multiple groups were performed with one-way analysis of variance (ANOVA). Statistical significance was denoted by a *p* \< 0.05. All data were presented as the mean ± SEM. All experiments were performed at least three times.

Results
=======

Specific gene expression patterns of the RA pathway in E7.5 mouse embryos
-------------------------------------------------------------------------

Retinol can be carried by retinol-binding protein 4 (*Rbp4*), and transferred into cytoplasm by a receptor named as stimulated by retinoic acid 6 (*Stra6*) [@B25]. After a series of dehydrogenation reactions, retinol is metabolized into all-trans retinoic acid (RA). RA regulates the transcriptional activity of target genes as a ligand for RAR/RXR heterodimers. In our previous study, we performed transcriptome analysis on E7.5 germ layers to identify functional genes for embryonic development and stem cell differentiation [@B20], [@B26]. The specific expressions of the germ layer markers indicated the embryo tissues were separated successfully ([Figure S1](#SM0){ref-type="supplementary-material"}). Among the differentially expressed genes, RA pathway genes showed specific expression patterns in three germ layers (Figure [1](#F1){ref-type="fig"}A-B). *Rbp4* and *Stra6* were highly expressed in the endoderm (Endo) and mesoderm (Meso), respectively, suggesting that RA synthesis depends on the cooperation of the endoderm and mesoderm. Furthermore, compared with the ectoderm (Ecto), the primitive streak (PS) highly expressed *Rbp1*, *Aldh1a2*, and *Crabp1*, which are involved in RA generation and signal transduction. These genes continued to be expressed in the mesoderm (Figure [1](#F1){ref-type="fig"}A-B). Thus, the RA pathway may have been primed in the primitive streak by the expression of RA synthases, and be triggered by *Stra6*, which was highly expressed in the mesoderm compared to primitive streak. In addition, *Cyp26a1*, a gene for RA degeneration, was mainly expressed in the endoderm (Figure [1](#F1){ref-type="fig"}A-B). These results suggest that RA pathway may play important roles in mesoderm differentiation. Since specific *STRA6* expression may provide clues for optimal time of RA treatment, we performed qPCR to detect its mRNA levels during cardiomyocyte differentiation of hESCs. *STRA6* mRNA was elevated at the mesoderm stage (days 2-4) and was increased dramatically in beating cardiomyocytes on day 15 of cardiomyocyte differentiation compared to undifferentiated cells (Figure [1](#F1){ref-type="fig"}C). Collectively, these results reveal that RA might play biphasic roles at these two specific stages during the differentiation of hESCs into cardiomyocytes.

RA treatment on days 2-4 is important for cardiomyocyte differentiation
-----------------------------------------------------------------------

With regards to the gene expression of RA pathway members, we focused on the effects of RA on the mesoderm and downstream cardiomyocyte differentiation. Firstly, RA was supplemented at different stages of cardiomyocyte differentiation ([Figure S2](#SM0){ref-type="supplementary-material"}A). The addition of RA during the first two days (days 0-2) dramatically inhibited the differentiation of the entire primitive streak (PS). Markers for the anterior PS (*FOXA2* and *GSC*), shared PS (*T* and *MIXL1*) and mid/posterior PS (*MESP1* and *EVX1*) were significantly decreased upon RA treatment ([Figure S2](#SM0){ref-type="supplementary-material"}B). RA treatment from day 2 to day 4 significantly inhibited the paraxial mesoderm marker *DLL1*, but enhanced the expression of lateral mesoderm markers (*FOXF1*, *KDR* and *PDGFRA*) ([Figure S2](#SM0){ref-type="supplementary-material"}C). RA treatment from day 4 to day 6 substantially inhibited the expression of cardiac progenitor markers (*ISL1*, *NKX2.5* and *TBX20*) and limb bud markers (*PRRX1* and *HOXB5*) ([Figure S2](#SM0){ref-type="supplementary-material"}D), consistent with previous publications [@B27]-[@B29]. RA treatment from day 6 to day 10 significantly inhibited endothelial markers (*CD31*, *CD34* and *CD144*) and myocardial markers (*NKX2.5*, *TNNT2*, *MYH7* and *MYH6*), but the epicardial marker *TBX18* was increased by RA treatment ([Figure S2](#SM0){ref-type="supplementary-material"}E), consistent with a previous study [@B18]. Taken together, the results suggest that RA mainly plays negative roles in cardiomyocyte differentiation but promotes lateral mesoderm differentiation, consistent with the *STRA6* expression at the mesoderm stage (days 2-4) of hESC differentiation and in E7.5 mouse mesoderm *in vivo*. Therefore, we assumed that RA treatment on days 2-4 should promote cardiomyocyte differentiation.

Flow cytometry analysis confirmed that RA treatment at the mesoderm stage (days 2-4) promoted cardiomyocyte differentiation, as evidenced by the increased proportion of TNNT2^+^ cells on day 10 of differentiation in H1 hESC line (Figure [2](#F2){ref-type="fig"}A-B). Furthermore, qPCR confirmed the upregulation of cardiomyocyte markers *TNNT2*, *NKX2.5* and *MYH6* (Figure [2](#F2){ref-type="fig"}C). Additionally, we used another hESC line, NKX2.5^eGFP/w^ hES3 to examine cardiomyocyte differentiation supplemented with RA on days 2-4 [@B30]. Similarly, RA treatment at this stage could promote gene expression of the lateral mesoderm markers on day 4 ([Figure S3](#SM0){ref-type="supplementary-material"}A) and increased cardiomyocyte proportions (eGFP^+^) on day 10 of differentiation ([Figure S3](#SM0){ref-type="supplementary-material"}B). Collectively, the results suggest that RA treatment on days 2-4 promotes lateral mesoderm differentiation, and subsequently enhances cardiomyocyte differentiation from hESCs.

In addition, we noticed that RA treatment (days 2-4) upregulated atrium-specific markers (*MYL7* and *SLN*) on day 25 of differentiation, while ventricular markers (*MYL2* and *IRX4*) were downregulated by RA treatment (Figure [2](#F2){ref-type="fig"}D-E). These results support that RA signaling at the lateral mesoderm stage of development is important for atrial differentiation. Therefore, RA treatment at the lateral mesoderm stage not only promotes the efficiency of cardiomyocyte differentiation but also atrial specification.

RA treatment on days 15-20 promotes RNA isoform switch and RNA splicing
-----------------------------------------------------------------------

The increased *STRA6* mRNA expression post beating indicated that the RA pathway might play an important role in the maturation of hESC-CMs. For maturation analysis, hESC-CMs were purified in CDM3 containing lactic acid and lacking of D-glucose for 4 days to remove noncardiomyocytes. Thereafter, we optimized the time window of RA treatment for cardiomyocyte maturation as indicated in Figure [3](#F3){ref-type="fig"}A. With the development of human heart and the maturation of human cardiomyocytes, the ratio of *MYH7*/*MYH6* increases and *MHY7* becomes the dominant isoform in human adult heart [@B5], [@B7], [@B10]. Thus, ratio of *MYH7*/*MYH6* was widely used as a reliable indicator for cardiomyocyte maturation [@B7], [@B31], [@B32]. Quantitative real-time PCR showed that *MYH7*/*MYH6* ratio was significantly increased in cardiomyocytes treated with RA on days 15-20 (Figure [3](#F3){ref-type="fig"}A). Thus, RA treatment on days 15-20 might accelerate cardiomyocyte maturation following the protocol in Figure [3](#F3){ref-type="fig"}B. Meanwhile, we analyzed the isoform switch using RNA-seq data. Genome browser snapshots confirmed the increased ratio *MYH7/MYH6* by RA treatment (Figure [3](#F3){ref-type="fig"}C). Furthermore, *TNNI3/TNNI1* ratio, another indicator of cardiomyocyte maturation [@B32], was also increased (Figure [3](#F3){ref-type="fig"}D). Moreover, RA treatment upregulated the expression of maturation marker genes related to calcium handling (*RYR2*, *SERCA2*, *CACNA1C*) and electrical conduction (*KCNJ2*, *SCN5A*) in hESC-CMs ([Figure S4](#SM0){ref-type="supplementary-material"}), consistent with cardiomyocyte maturation phenotypes in previous reports [@B7], [@B33]. These results were further verified in cardiomyocytes derived from H1 hESC line ([Figure S5](#SM0){ref-type="supplementary-material"}).

RNA splicing is a crucial layer in gene expression, which is important for cardiomyocyte maturation [@B34]. Previous studies have found some maturation-related splicing genes, including *TMED2*, *PUM1*, *LDB3* and *PKM* [@B34]-[@B38]. Our RNA-seq data provided the possibility for RNA splicing analysis. After RA treatment, we found *TMED2* showed reduced exon skipping (Figure [4](#F4){ref-type="fig"}A, [Figure S6](#SM0){ref-type="supplementary-material"}A). *PUM1* had alternative 3\' splice site (A3SS), and RA treatment promoted the selection of a longer *PUM1* variant (Figure [4](#F4){ref-type="fig"}B, [Figure S6](#SM0){ref-type="supplementary-material"}B). The short form of *LDB3* was increased in adult heart. In our study, RA-induced short *LDB3* up-regulation was consistent with cardiomyocyte maturation (Figure [4](#F4){ref-type="fig"}C, [Figure S6](#SM0){ref-type="supplementary-material"}C). The *PKM* gene has mutually exclusive exons. We observed increased splicing of *PKM1* after RA treatment (Figure [4](#F4){ref-type="fig"}D, [Figure S6](#SM0){ref-type="supplementary-material"}D), which is the adult variant of pyruvate kinase. Therefore, RA promotes cardiomyocyte maturation at RNA splicing level.

RA treatment on days 15-20 promotes structural maturation of hESC-CMs
---------------------------------------------------------------------

The morphology and structure of hESC-CMs on day 30 were further analyzed to confirm the mature phenotypes. Immunostaining with a sarcomeric α-actinin antibody indicated that RA treatment could substantially increase sarcomere length (Figure [5](#F5){ref-type="fig"}A). Quantitative analyses showed that RA-treated hESC-CMs exhibited significant increases in cell area (1436 ± 57 μm^2^ in the RA group versus 1230 ± 51μm^2^ in the DMSO group, *p*\<0.05) (Figure [5](#F5){ref-type="fig"}B) and sarcomere length (measured by the distance between z-disks, 1.89 ± 0.04 μm in the RA group versus 1.66 ± 0.04 μm in the DMSO group, *p*\<0.05) (Figure [5](#F5){ref-type="fig"}C). The percentage of multinucleated cardiomyocytes was significantly increased by RA treatment (Figure [5](#F5){ref-type="fig"}D). Taken together, these data demonstrate that RA treatment promotes the structural maturation of cardiomyocytes.

RA promotes electrophysiological maturation and calcium handling of hESC-CMs
----------------------------------------------------------------------------

To further verify the functional maturity of the hESC-CMs at an electrophysiological level, action potential was measured with patch clamp technique. The action potential duration at 50% repolarization (APD~50~) and APD~90~ were usually used to verify the maturity of cardiomyocytes [@B6], [@B39], [@B40]. In our study, APD~50~ was significantly prolonged in the RA-treated hESC-CMs (395.8 ± 47.7 ms in the RA group versus 280.4 ± 30.2 ms in the DMSO group, *p*\<0.05), and APD~90~ showed the similar trend after RA treatment (491.1 ± 54.3 ms in the RA group versus 337.0 ± 30.6 ms in the DMSO group, *p*\<0.05) (Figure [6](#F6){ref-type="fig"}A-C). These results were consistent with previous reports [@B6], [@B39], [@B40], implying RA promoted cardiomyocyte electrophysiological maturity.

To further examine the calcium handling of the hESC-CMs, we performed cardiomyocyte differentiation and calcium imaging using H9-GCaMP6f, which was the H9 hESC line with green fluorescent calcium-modulated protein 6 fast type (GCaMP6f) calcium sensor in the AAVS1 locus [@B24]. On day 30 of differentiation, calcium transients for the DMSO and RA groups were recorded. In the RA-treated CMs, the time to peak was decreased significantly (197.8 ± 21.7 ms in the RA group versus 344.6 ± 25.8 ms in the DMSO group, *p*\<0.01; Figure [6](#F6){ref-type="fig"}D-E). Meanwhile, the decay time were also decreased significantly after RA treatment (0.98 ± 0.06 sec in the RA group versus 1.19 ± 0.08 sec in the DMSO group, *p*\<0.05; Figure [6](#F6){ref-type="fig"}F). The amplitude of Ca^2+^ transient was unchanged by RA treatment (Figure [6](#F6){ref-type="fig"}G). Consistent with previous reports [@B9], [@B10], [@B40], these results indicate RA treatment promotes hESC-CM functional maturation, in term of electrophysiology and calcium handling.

RA promotes the metabolic switch from glycolysis to oxidative phosphorylation
-----------------------------------------------------------------------------

Adult cardiomyocytes preferentially use oxidative phosphorylation for energy generation [@B12]. Immunostaining using MitoTracker Red CMXRos showed that the distribution of mitochondria was not affected by RA treatment (Figure [7](#F7){ref-type="fig"}A), but the mitochondrial mass of hESC-CMs was significantly increased in RA-treated hESC-CMs compared to DMSO-treated hESC-CMs, as detected by flow cytometry (Figure [7](#F7){ref-type="fig"}B). The levels of*mtCO1* and *ND1* DNA are commonly used to evaluate mitochondrial DNA (mtDNA) [@B32], and our data indicated that mtDNA levels were substantially increased in RA-treated hESC-CMs compare to DMSO-treated hESC-CMs (Figure [7](#F7){ref-type="fig"}C).

Subsequently, we sought to determine whether the increased mitochondrial mass could enhance mitochondrial metabolism in RA-treated hESC-CMs. To analyze the mitochondrial metabolism, a Seahorse metabolic flux assay was performed with sequential additions of a mitochondrial ATP synthase inhibitor (oligomycin), a proton gradient discharger (FCCP), and electron inhibitors (rotenone/antimycin A), with D-glucose and sodium pyruvate in the detection medium (Figure [7](#F7){ref-type="fig"}D). Both the basal respiration and ATP production were unaffected, but the mitochondrial maximal respiration capacity and reserve capacity were significantly higher, as measured by the oxygen consumption rate (OCR), in RA-treated hESC-CMs than control (Figure [7](#F7){ref-type="fig"}E-H). Additionally, in H1 derived-cardiomyocytes, RA significantly promoted basal respiration, ATP production, mitochondrial maximal respiration capacity and reserve capacity ([Figure S7](#SM0){ref-type="supplementary-material"}). *PGC1A* is a mitochondrial activity-related gene [@B41]. We found *PGC1A* was significantly increased in RA-treated hESC-CMs (Figure [7](#F7){ref-type="fig"}I). ChIP-PCR demonstrated the direct binding of RARα to RAREs in *PGC1A* promoter after RA treatment ([Figure S8](#SM0){ref-type="supplementary-material"}). Collectively, these results demonstrate that RA promotes oxidative phosphorylation in hESC-CMs. We next investigated glycolysis in hESC-CMs using a Seahorse XF assay to assess extracellular acidification rates (ECAR). RA treatment substantially decreased glycolysis in hESC-CMs (Figure [7](#F7){ref-type="fig"}J-K), while the glycolytic capacity, glycolytic reserve and non-glycolytic acidification were not affected (Figure [7](#F7){ref-type="fig"}L-N). The downregulation of genes involved in glycolytic metabolism, such as*ENO1*, *ALDOA*, *LDHA* and *BPGM*, supported the decreased glycolysis in RA-treated hESC-CMs (Figure [7](#F7){ref-type="fig"}O). Together, these data demonstrate that RA promotes a metabolic switch from glycolysis to mitochondrial metabolism.

RA promotes fatty acid and pyruvate metabolism in the mitochondria of hESC-CMs
------------------------------------------------------------------------------

The energy sources of mitochondria mainly include pyruvate derived from glucose, acyl-CoA derived from fatty acids, and amino acids (such as glutamine). Although glycolysis was decreased in RA-treated hESC-CMs compared to DMSO-treated hESC-CMs, mitochondrial metabolism was significantly increased when the medium was supplemented with both glucose and pyruvate (Figure [7](#F7){ref-type="fig"}D), indicating that pyruvate might be the main energy source for mitochondria. We further detected OCR by supplying cells with either glucose or pyruvate. Interestingly, hESC-CMs preferred pyruvate over glucose. Furthermore, we found that glucose usage was decreased but that pyruvate usage was significantly increased in RA-treated hESC-CMs compared to DMSO-treated hESC-CMs (Figure [8](#F8){ref-type="fig"}A-E). Thus, exogenous pyruvate is an efficient substrate for acetyl-CoA production and the subsequent TCA cycle.

Mature cardiomyocytes mainly use fatty acids as energy resources for oxidative phosphorylation [@B42]. To examine the fatty acid metabolism in RA-treated hESC-CMs, we performed an FAO assay in the presence of palmitate. We found that the oxidation of palmitate was significantly higher in RA-treated hESC-CMs than in DMSO-treated hESC-CMs, as evidenced by the increased ATP production, maximal respiration and reserve capacity after RA treatment (Figure [8](#F8){ref-type="fig"}F-J). As an inhibitor of carnitine palmitoyltransferase-1, ETO inhibited fatty acid metabolism. RA-treated hESC-CMs showed increased ETO-responsive OCR change (Figure [8](#F8){ref-type="fig"}H-J), indicating RA could promote fatty acid metabolism.

Glutamine, which is widely used in cell culture, as an amino acid energy resource, can be catabolized to α-ketoglutarate and support TCA cycle anaplerosis. We found that the utilization of glutamine was comparable between RA-treated hESC-CMs and DMSO-treated hESC-CMs (Figure [8](#F8){ref-type="fig"}K-N).

Taken together, our data indicate that RA promotes fatty acid and pyruvate metabolism in the mitochondria of hESC-CMs (Figure [9](#F9){ref-type="fig"}). However, due to the limited glycolysis and endogenous metabolite pyruvate in RA-treated hESC-CMs, RA mainly promotes the utilization of fatty acids in hESC-CMs in the absence of exogenous pyruvate.

Discussion
==========

Studies on embryo biology are valuable resources, providing direct evidence for the mechanisms of stem cell differentiation [@B17], [@B43], [@B44]. As a ligand for the nuclear transcription factor RAR, RA exerts pleiotropic actions at different stages of heart development [@B14]. However, RA is not essential for cardiomyocyte differentiation *in vitro*, because hESCs can differentiate into cardiomyocytes in chemically defined medium without RA or retinol [@B16], [@B23]. Although the cardiomyocytes can be derived from hESCs, the differentiation efficiency and maturation of the derived cardiomyocytes still need to be improved. In this study, we identified two important stages for RA treatment to promote cardiomyocyte differentiation and maturation, respectively. We found that RA synthesis enzymes were primed in the primitive streak; however, *Stra6* was specifically expressed in the lateral mesoderm and was responsible for the transport of retinol into the cytoplasm, indicating that RA might be mainly synthesized in the lateral mesoderm after gastrulation. This result was consistent with the inhibitory function of RA treatment on primitive streak marker expression. Furthermore, we found that RA treatment on days 2-4 was important for lateral mesoderm development and downstream cardiomyocyte differentiation. Additionally, we observed RA treatment (days 2-4) promoted atrial-like cell specification and suppressed ventricular-like cell specification, consistent with a previous report [@B17].

During directed cardiomyocyte differentiation of human and mouse pluripotent stem cells, RA treatment after primitive streak formation was mainly used for atrial-like cardiomyocyte induction. However, the time interval for RA addition is not consistent at different induction conditions and in different species. In human PSC studies, Zhang Q *et al.* added RA (1 μM) on day 5-8 of differentiation to induce atrial-like cardiomyocyte in monolayer condition [@B18], whereas, Lee JH *et al*. added RA (500 nM) on day 3-5 using embryoid body-based condition [@B17]. Besides, the inhibitors and cytokines used in these studies were not consistent because of different protocols, which may affect the time interval of RA treatment. In this study, we optimized the RA treatment time interval of day 2-4 in monolayer condition with chemical defined medium based on the development evidence. In addition to atrial-like cardiomyocyte specification, RA significantly enhanced cardiomyocyte differentiation. Thus, our study provided a novel insight to optimize the RA treatment time for maximal atrial-like cardiomyocyte induction at different induction conditions. In mouse ESC studies, RA treatment on day 5-15 promotes cardiomyocyte differentiation of ESC line D3 using embryoid body method [@B45], and addition of RA on day 5-15 promotes atrial-like cell differentiation in 129/Ola-derived ESC lines [@B46]. Collectively, these human and mouse studies indicate RA concentration and treatment time interval should be optimized in different cell lines and different induction conditions to achieve the best effect.

Previous study has shown the functions of RA pathway during cardiac development and differentiation is conserved across species [@B17]. Our results proved that RA promoted *KDR* expression during hESC differentiation. Consistently, RA induced *Kdr* expression during mouse ESC differentiation [@B47], indicating its conserved role in lateral mesoderm differentiation. RA pathway activation could induce atrial-like cardiomyocytes from pluripotent stem cells in mouse, monkey and human [@B18], [@B48], [@B49], which was also proved in current hESC study, consistent with its role for atrial chamber development in mouse embryo [@B15]. Furthermore, we found RA promoted hESC-CM maturation, consistent with the structurally immature phenotype of ventricle cardiomyocytes in mouse RA-deficient embryos [@B15]. These results support the conserved role of RA in cardiomyocyte maturation, but there may be some difference between mouse and human. *MHY7* is the dominant isoform in human adult heart, and the ratio of *MYH7*/*MYH6* was increased after RA treatment in our study. Whereas, *Myh6* is the dominant isoform in mouse adult heart [@B10]. Whether mouse *Myh7*/*Myh6* is decreased by RA treatment needs to be investigated further.

Human ESC-CMs are powerful tools for heart disease modeling and drug screening [@B19], but their immature structures and metabolic properties have limited their application. In this study, although RA-treated hESC-CMs did not fully resemble adult-like cardiomyocytes, RA significantly promoted cardiomyocyte structural, electrophysiological and metabolic maturation. It is well known that RA exerts its effects through activation of RAR/RXR and PPAR/RXR heterodimers [@B50], and both of these receptors have been reported to promote fatty acid oxidation [@B51]-[@B53], supporting our results regarding the metabolic switch from glucose to fatty acid metabolism in RA-treated hESC-CMs. Moreover, the integration of RA and extracellular matrix supplementation may further accelerate hESC-CM maturation, because the extracellular matrix can promote the RAR expression and nuclear localization [@B54]. This may be important for the full activation of RA signaling and needs to be further investigated.

Pyruvate dehydrogenase kinase 4 (*PDK4*) functions as an inhibitor of pyruvate dehydrogenase (PDH), which converts pyruvate into acetyl-coA and thereby increases the utilization of acetyl-coA from glycolysis in the TCA cycle. Overexpression of *Pdk4* in mouse hearts decreases glucose oxidation and increases fatty acid metabolism correspondingly [@B35]. Therefore, its inhibitory effect on PDH activity reduces the use of pyruvate from glucose, and in turn resulted in the influx of acetyl-coA from fatty acid beta-oxidation into TCA cycle [@B43]. In our study, we found that *PDK4* was significantly upregulated by RA treatment ([Figure S9](#SM0){ref-type="supplementary-material"}), which was consistent with the increased fatty acid oxidation in RA-treated hESC-CMs. Furthermore, although the glucose oxidation levels were low in both DMSO- and RA-treated groups overall, they were further reduced by RA treatment, consistent with PDK4 upregulation. When supplied with exogenous pyruvate, RA-treated hESC-CMs showed the elevated mitochondrial oxidative phosphorylation, inconsistent with *PDK4* upregulation. Thus, exogenous pyruvate metabolism may not depend on PDK4. In this study, we also found some splicing evidences, supporting the role of RA in cardiomyocyte metabolic maturation. *PKM* encodes pyruvate kinase and can generate *PKM1* and *PKM2* subtypes by alternative splicing of mutually exclusive exon 9 and 10, respectively. *PKM2* is expressed in the fetal heart, and is replaced by *PKM1* by postnatal day 14.5, indicating *PKM1* is related with cardiomyocyte maturation [@B38]. The high activity PKM1 promotes the use of pyruvate in TCA cycle, while PKM2 facilitates pyruvate to convert to lactate [@B55], [@B56]. The upregulation of PKM1 in RA-treated cardiomyocyte was consistent with the increased exogenous pyruvate metabolism in mitochondria. Thus, the pyruvate metabolism was regulated at multiple levels and needs further investigation. Collectively, the core function of RA on hESC-CM metabolism is promoting mitochondrial oxidative phosphorylation. This phenomenon was also found in RA-induced differentiated SH-SY5Y cells and adipocytes [@B57]-[@B59], indicating RA might play the conserved roles on metabolism in these cell lines.

Previous studies had demonstrated the RA receptor complex RAR/RXR could bind to RAREs and regulate target genes directly [@B14], [@B25], [@B60]. Using ChIP-PCR, we found RAR could bind to the RAREs in *PGC1A* promoter and thus regulate metabolic gene directly. Whereas, ChIP-PCR did not identify the binding of RAR to *MYH6* and *MYH7* promoters (data not shown), indicating the effect of RA on *MYH7*/*MYH6* ratio might be indirect. Therefore, RA affects cardiomyocyte differentiation and maturation through both direct and indirect mechanisms.

In addition, the mechanism for RA-mediated splicing is still mysterious. It is reported that RA treatment can regulate RNA splicing through the ubiquitous nuclear protein Acinus in a dose- and time-dependent manner, and the splicing activity of Acinus is mediated by RA-activated RAR [@B61]. Moreover, as a nuclear receptor coactivator, *PGC1A* affects splicing decisions [@B62]. In our study, *PGC1A* was upregulated by RA treatment. Thus, RA treatment may affect splicing efficiency through these coregulators. However, the detailed mechanisms of RA in cardiomyocyte need to be further investigated.

In this study we found that RA promoted cardiomyocyte maturation in certain properties. RA-treated cardiomyocytes showed the improved maturation properties, including ultrastructure, cell area, oxidative metabolism, functional electrophysiology and calcium handling. However, these properties didn\'t reach the fully mature level of adult cardiomyocytes. As a single molecule, RA couldn\'t be expected to substantially induce hPSC-CM maturation like fully-developed cardiomyocytes isolated from adult heart, but it is an indispensable part of the orchestra. With the enrichment of the orchestra by different stimuli, including electromechanical stimulation, patterned biomaterials, developmental signal manipulation, metabolic stimulation and so on, fully mature cardiomyocytes might be obtained from hPSCs in the future [@B9], [@B10], [@B63], [@B64].

In conclusion, we found that RA was a critical factor for efficient lateral mesoderm differentiation in a confined time window, and subsequently promoted cardiomyocyte differentiation. More importantly, RA accelerated the structural, electrophysiological and metabolic maturation of hESC-CMs. Finally, we have provided a novel strategy to promote cardiomyocyte maturation through supplementation with RA.
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![**Specific gene expression patterns of the RA pathway in E7.5 mouse embryos and during human cardiomyocyte differentiation.** (**A**) Heatmap showed the expression patterns of genes involved in RA synthesis and degradation in the endoderm (Endo), mesoderm (Meso), ectoderm (Ecto) and primitive streak (PS) from E7.5 mouse embryos. (**B**) Real-time PCR showed the expression of RA synthesis and degradation genes in mouse Endo, Meso, Ecto and PS on E7.5. (**C**) Real-time PCR showed a biphasic expression pattern of *STRA6* during cardiomyocyte differentiation from hESCs. One-way ANOVA; \**p*\<0.05; \*\**p*\<0.01.](thnov10p9686g001){#F1}

![**RA treatment on days 2-4 promotes cardiomyocyte differentiation.** (**A**) Schematic diagram of cardiomyocyte differentiation from hESCs. (**B**) Flow cytometry analysis of differentiated cardiomyocyte (day 10) showed that the proportion of TNNT2^+^ cells was increased after RA treatment. (**C**) Real-time PCR showed that RA promoted the expression of cardiomyocyte-specific markers on day 10 of differentiation. (**D-E**) Real-time PCR showed the expression patterns of the atrium-specific markers (*MYL7* and *SLN*) and ventricular markers (*MYL2* and *IRX4*) on day 25 of differentiation. Student\'s *t*-test; \**p*\<0.05; \*\**p*\<0.01.](thnov10p9686g002){#F2}

![**RA promotes RNA isoform switch to the maturation-related form.** (**A**) Schematic diagram of cardiomyocyte maturation induction. Purified cardiomyocytes were treated with RA at different time intervals. All samples were harvested on day 30. Real-time PCR showed the expression patterns and ratio of the maturation-related genes *MYH7* and *MYH6* after RA treatment at different time intervals. (**B**) Defined schematic diagram for purification and maturation of cardiomyocytes with RA treatment. **(C)** RNA-seq coverage showed the increased *MYH7*/*MYH6* ratio in RA-treated hESC-CMs. **(D)** RNA-seq coverage showed the increased *TNNI3*/*TNNI1* ratio in RA-treated hESC-CMs.](thnov10p9686g003){#F3}

![**Sashimi Plot shows the alternative splicing of maturation-related genes.** (**A**) Sashimi Plot showed the reduced exon skipping of*TMED2* gene in RA-treated cardiomyocytes. (**B**) Sashimi Plot showed alternative 3\' splice site (A3SS) of*PUM1* gene. (**C**) RA promoted the expression of short *LDB3*. (**D**) Sashimi Plot showed alternative splicing of *PKM* gene, which had mutually exclusive exon 9 and 10.](thnov10p9686g004){#F4}

![**RA promotes structural maturation of hESC-CMs.** (**A**) Immunostaining of sarcomeric α-actinin (red) and nuclear counterstaining with Hoechst 33342 (Blue) in DMSO- and RA-treated hESC-CMs. Scale bars, 50 µm. (**B**) Quantitative analyses of immunostaining showed that cell area was increased in RA-treated hESC-CMs. (**C**) Quantitative analyses of immunostaining showed that sarcomere length was increased in RA-treated hESC-CMs. (**D**) Quantitative analyses of immunostaining showed that multinucleation was increased in RA-treated hESC-CMs. n \> 50 for each group. Student\'s *t*-test; \**p*\<0.05; \*\**p*\<0.01.](thnov10p9686g005){#F5}

![**RA promotes electrophysiological maturation and calcium handling of hESC-CMs.** (**A**) Representative spontaneous action potential recordings from the DMSO and RA-treated hESC-CMs. (**B-C**) APD~50~ (B) and APD~90~ (C) were increased in RA-treated hESC-CMs. n=21 for DMSO group and n =22 for RA group. (**D**) Representative intracellular calcium transients from DMSO and RA-treated hESC-CMs. (**E-F**) The time to peak (E) and decay time (F) were decreased in RA-treated hESC-CMs. n=19 for each group. (**G**) The amplitude of calcium transient was comparable in the two groups. Student\'s *t*-test; \**p*\<0.05; \*\**p*\<0.01, and ns, not significant.](thnov10p9686g006){#F6}

![**RA promotes the metabolic switch from glycolysis to oxidative phosphorylation.** (**A**) The distribution of mitochondria was not altered in RA-treated hESC-CMs. MitoTracker Red CMXRos (red), TNNT2 (green) and Hoechst 33342 nuclear stain (blue) were shown. (**B**) Flow cytometry showed that RA promoted the mitochondrial content of hESC-CMs. (**C**) Real-time PCR showed that the mitochondrial DNA copy number, calculated as mtCO1 or ND1/nuclear DNA content, was significantly higher in RA-treated hESC-CMs than in DMSO-treated hESC-CMs. **(D)** Representative OCR traces of the DMSO- and RA-treated hESC-CMs in the presence of both glucose and pyruvate obtained using a Seahorse XF24 Extracellular Flux Analyzer. **(E-H)** Quantification of basal respiration (E), ATP production (F), maximal respiration (G) and reserve capacity (H) in the DMSO- and RA-treated hESC-CMs in the presence of both glucose and pyruvate. **(I)** Real-time PCR showed increased *PGC1A* mRNA expression in RA-treated hESC-CMs. (**J**) Representative ECAR traces of DMSO- and RA-treated hESC-CMs obtained to investigate glycolysis using a Seahorse XF24 Extracellular Flux Analyzer. (**K-N**) Quantification of the glycolysis (K), glycolytic capacity (L), glycolytic reserve (M) and non-glycolytic acidification (N) in DMSO- and RA-treated hESC-CMs. (**O**) Real-time PCR showed that glycolysis-related genes were significantly downregulated after RA treatment. All measurements were normalized to the 10 µg of protein. Student\'s *t*-test; \**p*\<0.05; \*\**p*\<0.01, and; ns, not significant.](thnov10p9686g007){#F7}

![**RA promotes mitochondrial metabolism via fatty acids and pyruvate.** (**A**) Representative OCR traces of DMSO- and RA-treated hESC-CMs in the presence of either glucose or pyruvate. **(B-E)** Quantification of basal respiration (B), ATP production (C), maximal respiration (D) and reserve capacity (E) in DMSO and RA-treated hESC-CMs in the presence of either glucose or pyruvate. (**F**) Representative OCR traces of DMSO- or RA-treated hESC-CMs in the presence of sodium palmitate obtained to assess fatty acid metabolism. ETO-responsive OCR changes were used to confirm fatty acid metabolism. **(G-J)** Quantification of basal respiration (G), ATP production (H), maximal respiration (I) and reserve capacity (J) in DMSO- and RA-treated hESC-CMs in the presence of sodium palmitate to assess fatty acid metabolism. (**K**) Representative OCR traces of DMSO- or RA-treated hESC-CMs in the presence of GlutaMAX obtained using a Seahorse XF24 Extracellular Flux Analyzer. **(L-N)** Quantification of the basal respiration (L), ATP production (M) and maximal respiration (N) in DMSO- and RA-treated hESC-CMs in the presence of GlutaMAX. All measurements were normalized to the 10 µg of protein. Student\'s *t*-test; \**p*\<0.05; \*\**p*\<0.01, and ns, not significant.](thnov10p9686g008){#F8}

![**Effects of RA on metabolic changes in cardiomyocytes.** After RA treatment on days 15-20, glycolysis in cardiomyocytes was decreased, (as indicated by the green arrows), whereas mitochondrial metabolism was increased, as evidenced by increased fatty acid and pyruvate usage (as indicated by the red arrows). These results supported the metabolic maturation of cardiomyocytes after RA treatment.](thnov10p9686g009){#F9}
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